RENAL DENERVATION TREATMENT FOR UNCONTROLLED HYPERTENSION | INNOVATIVE TECHNOLOGY UPDATE

Sunday, March 9, 2025

8:00 AM – 9:56 AM ET

Moderator(s)

David E. Kandzari, MD, FACC, FSCAI

Director, Interventional Cardiology, Piedmont Heart Institute; Chief Scientific Officer, Piedmont Healthcare
Piedmont Heart Institute
Atlanta, Georgia, United States

Disclosure information not submitted.
Michael J. Bloch, MD

Medical Director, Vascular Care
Renown Institute for Heart and Vascular Health
reno, Nevada, United States

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); baralogics: Consulting Fees (e.g., advisory boards) (Ongoing); corcept: Consulting Fees (e.g., advisory boards) (Ongoing); esperion: Consulting Fees (e.g., advisory boards) (Ongoing); idorsia pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); janssen: Consulting Fees (e.g., advisory boards) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SoniVie: Grant/Research Support (Ongoing)

Disclosure(s):

Michael J. Bloch, MD: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); baralogics: Consulting Fees (e.g., advisory boards) (Ongoing); corcept: Consulting Fees (e.g., advisory boards) (Ongoing); esperion: Consulting Fees (e.g., advisory boards) (Ongoing); idorsia pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); janssen: Consulting Fees (e.g., advisory boards) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SoniVie: Grant/Research Support (Ongoing)